Casgevy, exagamglogene autotemcel
Named-patient access overview. Casgevy is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Casgevy
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Casgevy
Casgevy (exagamglogene autotemcel) is manufactured by Vertex/CRISPR and indicated for Sickle cell disease; transfusion-dependent beta-thalassemia. It is a Gene edit (CRISPR) approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Casgevy
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Casgevy for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Casgevy is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Casgevy in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Casgevy
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.